Objective: We aimed to investigate the efficacy of flumazenil infusion in the maintenance of arousal and prevention of development of complications in severe benzodiazepine poisoning.
Materials And Method: Sixty severely poisoned patients (intubated due to loss of consciousness) intoxicated by sole benzodiazepines referred to Loghman Hakim hospital between May 2018 and August 2019 were considered to be included in the current study. All were evaluated for possible contraindications of flumazenil administration. If there were no contraindications, we continued supportive care in one group and supportive care plus flumazenil infusion in the second group. Following response to the stat dose of flumazenil, complications, hospital stay, and outcome were compared between these two groups.
Results: A total of 60 benzodiazepine-poisoned patients aged between 16 and 84 years old (37 males and 23 females) were enrolled. There was no statistically significant difference between these two groups regarding the period of hospital stay. Need for intubation significantly decreased in the infusion group. None of the patients experienced seizure or dysrhythmia. One patient died in the control group which received only a stat dose of flumazenil.
Conclusions: Administration of flumazenil is safe in benzodiazepine-poisoned patients with appropriate indications. Flumazenil infusion can significantly decrease the need for intubation and subsequent ICU admission. Even though flumazenil is an expensive antidote, its administration may decrease the need for ICU beds in the setting of acute poisoning.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00228-020-03031-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Remimazolam for Sedation and Trachospray for Topicalization During Flexible Nasal Intubation in a Spontaneously Breathing Patient.
Cureus
January 2025
Anesthesiology and Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, NLD.
When a difficult airway is anticipated, awake tracheal intubation can be considered. Usually, low doses of sedatives are administered during this procedure for minimal sedation and anxiolysis, such as midazolam and remifentanil. The newly developed ultra-short-acting benzodiazepine remimazolam has a pharmacokinetic profile that is more suitable for titration during awake tracheal intubation than the long-acting midazolam.
View Article and Find Full Text PDFComparison of remimazolam and sevoflurane for general anesthesia during transcatheter aortic valve implantation: a randomized trial.
Can J Anaesth
December 2024
Department of Anesthesiology and Critical Care Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Purpose: Safe perioperative management of patients undergoing transcatheter aortic valve implantation (TAVI) is crucial. Remimazolam is a newly developed short-acting benzodiazepine. We hypothesized that combining remimazolam and flumazenil would reduce emergence time compared with sevoflurane in patients undergoing general anesthesia for TAVI.
View Article and Find Full Text PDFAge-Related Response to Remimazolam among Older Patients Undergoing Orthopedic Surgery: A Single-Center Prospective Observational Study.
Medicina (Kaunas)
October 2024
Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
: Remimazolam, an ultra-short-acting benzodiazepine, is increasingly used in procedural sedation and general anesthesia. It is characterized by rapid onset of action, inactive metabolites, no delay in recovery, and few adverse events. Its hemodynamic and respiratory stability are comparable to other anesthetics, and it is safe in high-risk and geriatric patients.
View Article and Find Full Text PDFIn vivo biomarkers of GABAergic function in epileptic rats treated with the GAT-1 inhibitor E2730.
Epilepsia
November 2024
The Department of Neuroscience, Monash University, Melbourne, Australia.
Article Synopsis
- E2730 is a GABA transporter-1 inhibitor that shows significant anti-seizure effects in a rodent model of chronic temporal lobe epilepsy, specifically the kainic acid status epilepticus (KASE) rat model.
- A randomized cross-over study revealed that E2730 treatment resulted in a notable reduction of spontaneous seizures, with 73% of the treated animals becoming seizure-free and alterations in various neuroimaging measures indicating changes in GABAergic function.
- The study found that while E2730 lowered taurine levels and affected gamma frequency oscillations in the brain, it did not change GABA receptor affinity or density, highlighting its complex impact on brain neurotransmission during seizure management.
Effect of Remimazolam on Transcranial Electrical Motor-evoked Potential in Spine Surgery: A Prospective, Preliminary, Dose-escalation Study.
J Neurosurg Anesthesiol
July 2024
Department of Anesthesiology, Niigata University Medical and Dental Hospital, Niigata.
Article Synopsis
- The study explores the impact of remimazolam, a new anesthetic, on motor-evoked potentials (MEPs) during general anesthesia in patients undergoing spinal fusion surgery.
- Ten adult patients were monitored with varying doses of remimazolam to determine whether higher doses affected MEP amplitude.
- Results indicated no significant difference in MEP amplitude after increasing the dose, suggesting remimazolam may have a minimal impact on these electrical signals in the brain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!